We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Valeant efforts

27 July 2011 By Quentin Webb

Valeant, the dealhungry North American drugmaker, may have its eyes on Meda, its $3.5 bln Swedish lookalike. Both prefer growth through M&A to heavy spending on research. But the similarities do not point to synergies. Scant geographic overlap also argues against a merger.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)